Non-renal cell carcinoma of kidney – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:03 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Non-renal cell carcinoma of kidney – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Pembrolizumab and Enfortumab Vedotin for Patients with Collecting Duct and Renal Medullary Carcinoma https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-enfortumab-vedotin-for-patients-with-collecting-duct-and-renal-medullary-carcinoma/ Wed, 29 Apr 2026 15:03:49 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-enfortumab-vedotin-for-patients-with-collecting-duct-and-renal-medullary-carcinoma/ This clinical trial is focused on studying two types of kidney cancer: Collecting Duct Carcinoma and Medullary Renal Cell Carcinoma. The study will use a combination of two treatments: Pembrolizumab, also known by its code name MK-3475, and Enfortumab Vedotin. Pembrolizumab is a type of medication called a humanized antibody, which helps the immune system fight cancer cells. Enfortumab Vedotin is an antibody-drug conjugate, which means it combines an antibody with a drug to target and kill cancer cells more effectively.

The purpose of this study is to evaluate how well the combination of Pembrolizumab and Enfortumab Vedotin works in treating these specific types of kidney cancer. Participants in the study will receive these medications through an infusion, which is a way of delivering the treatment directly into the bloodstream. The study will last for a period of up to 36 months, during which the effectiveness of the treatment will be monitored. Some participants may receive a placebo, which is a substance with no active medication, to compare the results.

The main goal of the study is to determine the Objective Response Rate (ORR), which measures how well the cancer responds to the treatment. Secondary goals include assessing progression-free survival (PFS), which is the length of time during and after treatment that the cancer does not get worse, and overall survival (OS), which is the length of time participants live after starting the treatment. The study will also look at how well participants tolerate the treatment. The trial is expected to continue until December 2029.

]]> Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials https://clinicaltrials.eu/trial/56496/ Wed, 29 Apr 2026 14:29:10 +0000 https://clinicaltrials.eu/trial/56496/ This study focuses on evaluating a medication called tazemetostat, which is given as a film-coated tablet taken by mouth. The study aims to assess the long-term safety of this medication in patients who have previously been treated with tazemetostat in other clinical trials and have shown benefit from the treatment.

The study will monitor patients who continue taking tazemetostat either alone or in combination with other approved or experimental medications. During the study, researchers will track any side effects that may occur and how well patients tolerate the medication over an extended period. The medication will be provided according to each patient’s previous treatment plan.

Participants will be monitored for various health measures, including their blood cell counts, kidney function, and liver function. The study will also track how long patients survive while receiving the treatment. This is an open-label study, which means all participants will receive the active medication, and there is no use of a placebo.

]]>